186 related articles for article (PubMed ID: 21173787)
1. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Yamada Y; Arao T; Nishio K; Michalowski A; Green JE
Pharmacogenomics J; 2012 Apr; 12(2):119-27. PubMed ID: 21173787
[TBL] [Abstract][Full Text] [Related]
2. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Michalowski A; Green JE
PLoS One; 2011 Feb; 6(2):e16694. PubMed ID: 21364753
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
4. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
5. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
[TBL] [Abstract][Full Text] [Related]
6. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim JS; Kim MA; Kim TM; Lee SH; Kim DW; Im SA; Kim TY; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Choe KJ; Kim NK
Br J Cancer; 2009 Mar; 100(5):732-8. PubMed ID: 19259093
[TBL] [Abstract][Full Text] [Related]
8. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
9. Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Kitamura S; Tanahashi T; Aoyagi E; Nakagawa T; Okamoto K; Kimura T; Miyamoto H; Mitsui Y; Rokutan K; Muguruma N; Takayama T
Oncology; 2017; 93(2):127-135. PubMed ID: 28511180
[TBL] [Abstract][Full Text] [Related]
10. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
12. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
13. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Al-Batran SE; Pauligk C; Wirtz R; Werner D; Steinmetz K; Homann N; Schmalenberg H; Hofheinz RD; Hartmann JT; Atmaca A; Altmannsberger HM; Jäger E
Ann Oncol; 2012 Jul; 23(7):1699-705. PubMed ID: 22112973
[TBL] [Abstract][Full Text] [Related]
14.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
17. Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer.
Wang X; Liu Y; Shao D; Qian Z; Dong Z; Sun Y; Xing X; Cheng X; Du H; Hu Y; Li Y; Li L; Dong B; Li Z; Wu A; Wu X; Bu Z; Zong X; Zhu G; Ji Q; Wen XZ; Zhang LH; Ji JF
Gastric Cancer; 2016 Jan; 19(1):116-27. PubMed ID: 25618371
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.
Kim HK; Green JE
Pharmacogenomics; 2014 Feb; 15(3):375-84. PubMed ID: 24533716
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Marabotti C; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3205-9. PubMed ID: 17664467
[TBL] [Abstract][Full Text] [Related]
20. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
